Momenta, Sandoz develop and market complex drugs; expanded in separate deal
Momenta (sugar sequencing and engineering) will combine its complex sugars technologies with the expertise of Novartis' generic unit Sandoz to jointly develop and market a generic equivalent of injectable enoxaparin--generic of Lovenox-- and potential improved forms of it. The drug is a low-molecular weight heparin for preventing and treating deep vein thrombosis and for treating acute coronary syndromes.
- Generic Drugs
- Drug Discovery Tools
- Large Molecule
- Includes Contract
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com